Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients

References

• MohrJJohnsonMCooperTLewisJSOstrosky-ZeichnerLCurrent options in antifungal pharmacotherapyPharmacotherapy200828561464518447660
   PubMed Web of Science ®Google Scholar
• MiceliMHDíazJALeeSAEmerging opportunistic yeast infectionsLancet Infect Dis20111114215121272794
   PubMed Web of Science ®Google Scholar
• MiceliMHLeeSAEmerging moulds: epidemiological trends and antifungal resistanceMycoses2011546e666e67821672045
   PubMed Web of Science ®Google Scholar
• BormanAMPetchRLintonCJPalmerMDBridgePDJohnsonEMCandida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agentsJ Clin Microbiol200846393393818199788
   PubMed Web of Science ®Google Scholar
• SnydmanDRShifting patterns in the epidemiology of nosocomial Candida infectionsChest20031235 Suppl500S503S12740235
   PubMed Web of Science ®Google Scholar
• PfallerMADiekemaDJGibbsDLResults from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997–2005. An 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole by CLSI standardized disk diffusion testingJ Clin Microbiol20074561735174517442797
   PubMed Web of Science ®Google Scholar
• BaddleyJWMoserSAEmerging fungal resistanceClin Lab Med2004243721735vii15325062
   PubMed Web of Science ®Google Scholar
• SabatelliFPatelRMannPAIn vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeastsAntimicrob Agents Chemother20065062009201516723559
   PubMed Web of Science ®Google Scholar
• ImhofABalajeeSAFredricksDNEnglundJAMarrKABreakthrough fungal infections in stem cell transplant recipients receiving voriconazoleClin Infect Dis200439574374615356792
   PubMed Web of Science ®Google Scholar
• KobayashiKKamiMMurashigeNKishiYFujisakiGMitamuraTBreakthrough zygomycosis during voriconazole treatment for invasive aspergillosisHaematologica20048911ECR4215533847
   PubMedGoogle Scholar
• MartyFMCosimiLABadenLRBreakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplantsN Engl J Med2004350995095214985500
   PubMed Web of Science ®Google Scholar
• ProcopGWRobertsGDEmerging fungal diseases: the importance of the hostClin Lab Med2004243691719vivii15325061
   PubMed Web of Science ®Google Scholar
• AsciogluSRexJHde PauwBDefining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensusClin Infect Dis200234171411731939
   PubMed Web of Science ®Google Scholar
• ChandrasekarPInvasive mold infections: recent advances in management approachesLeuk Lymphoma200950570371519337880
   PubMed Web of Science ®Google Scholar
• RuhnkeMBohmeABuchheidtDDiagnosis of invasive fungal infections in hematology and oncology – guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO)Ann Oncol Epub 2011 Sep 23
   Web of Science ®Google Scholar
• FreifeldAGBowEJSepkowitzKAClinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of americaClin Infect Dis2011524e56e9321258094
   PubMed Web of Science ®Google Scholar
• GhannoumMARiceLBAntifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistanceClin Microbiol Rev199912450151710515900
   PubMed Web of Science ®Google Scholar
• SucherAJChahineEBBalcerHEEchinocandins: the newest class of antifungalsAnn Pharmacother200943101647165719724014
   PubMed Web of Science ®Google Scholar
• WalshTJDriscollTMilliganPAPharmacokinetics, safety, and tolerability of voriconazole in immunocompromised childrenAntimicrob Agents Chemother201054104116412320660687
   PubMed Web of Science ®Google Scholar
• MoenMDLyseng-WilliamsonKAScottLJLiposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infectionsDrugs200969336139219275278
   PubMed Web of Science ®Google Scholar
• DupontBOverview of the lipid formulations of amphotericin BJ Antimicrob Chemother200249Suppl 1313611801578
   PubMed Web of Science ®Google Scholar
• AnaissieEPaetznickVProffittRAdler-MooreJBodeyGPComparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin BEur J Clin Microbiol Infect Dis19911086656681748123
   PubMed Web of Science ®Google Scholar
• HawkinsJLBaddourLMCandida lusitaniae infections in the era of fluconazole availabilityClin Infect Dis2003362e14e1812522762
   PubMed Web of Science ®Google Scholar
• KrcmeryVBarnesAJNon-albicans Candida spp causing fungaemia: pathogenicity and antifungal resistanceJ Hosp Infect200250424326012014897
   PubMed Web of Science ®Google Scholar
• ColomboALMeloASCrespo RosasRFOutbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapyDiagn Microbiol Infect Dis200346425325712944016
   PubMed Web of Science ®Google Scholar
• Araujo RibeiroMAlastruey-IzquierdoAGomez-LopezARodriguez-TudelaJLCuenca-EstrellaMMolecular identification and susceptibility testing of Trichosporon isolates from a Brazilian hospitalRev Iberoam Micol200825422122519071890
   PubMed Web of Science ®Google Scholar
• PfallerMADiekemaDJRare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatusJ Clin Microbiol200442104419443115472288
   PubMed Web of Science ®Google Scholar
• BaddleyJWPappasPGSmithACMoserSAEpidemiology of Aspergillus terreus at a university hospitalJ Clin Microbiol200341125525552914662934
   PubMed Web of Science ®Google Scholar
• IwenPCRuppMELangnasANReedECHinrichsSHInvasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literatureClin Infect Dis1998265109210979597234
   PubMed Web of Science ®Google Scholar
• SuttonDASancheSERevankarSGFothergillAWRinaldiMGIn vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazoleJ Clin Microbiol19993772343234510364610
   PubMed Web of Science ®Google Scholar
• VerweijPEvan den BerghMFRathPMde PauwBEVossAMeisJFInvasive aspergillosis caused by Aspergillus ustus: case report and reviewJ Clin Microbiol19993751606160910203536
   PubMed Web of Science ®Google Scholar
• IwenPCRuppMEBishopMRDisseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantationJ Clin Microbiol19983612371337179817905
   PubMed Web of Science ®Google Scholar
• PanackalAAImhofAHanleyEWMarrKAAspergillus ustus infections among transplant recipientsEmerg Infect Dis200612340340816704776
   PubMed Web of Science ®Google Scholar
• BalajeeSAGribskovJLHanleyENickleDMarrKAAspergillus lentulus sp. nov, a new sibling species of A. fumigatusEukaryot Cell20054362563215755924
   PubMedGoogle Scholar
• BalajeeSAWeaverMImhofAGribskovJMarrKAAspergillus fumigatus variant with decreased susceptibility to multiple antifungalsAntimicrob Agents Chemother20044841197120315047520
   PubMed Web of Science ®Google Scholar
• PujolIGuarroJGenéJSalaJIn-vitro antifungal susceptibility of clinical and environmental Fusarium spp strainsJ Antimicrob Chemother19973921631679069536
   PubMed Web of Science ®Google Scholar
• DenningDWEchinocandin antifungal drugsLancet200336293901142115114550704
   PubMed Web of Science ®Google Scholar
• van BurikJAHareRSSolomonHFCorradoMLKontoyiannisDPPosaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 casesClin Infect Dis2006427e61e6516511748
   PubMed Web of Science ®Google Scholar
• Cuenca-EstrellaMRuiz-DíezBMartinez-SuárezJVMonzónARodríguez-TudelaJLComparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermumJ Antimicrob Chemother199943114915110381115
   PubMed Web of Science ®Google Scholar
• WalshTJPeterJMcGoughDAFothergillAWRinaldiMGPizzoPAActivities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydiiAntimicrob Agents Chemother1995396136113647574531
   PubMed Web of Science ®Google Scholar
• PerdomoHSuttonDAGarciaDSpectrum of clinically relevant Acremonium species in the United StatesJ Clin Microbiol201149124325621068274
   PubMed Web of Science ®Google Scholar
• GallisHADrewRHPickardWWAmphotericin B: 30 years of clinical experienceRev Infect Dis19901223083292184499
   PubMedGoogle Scholar
• WhiteMHBowdenRASandlerESRandomized, double-blind clinical trial of amphotericin B colloidal dispersion vs amphotericin B in the empirical treatment of fever and neutropeniaClin Infect Dis19982722963029709879
   PubMed Web of Science ®Google Scholar
• Ostrosky-ZeichnerLMarrKARexJHCohenSHAmphotericin B: time for a new “gold standard”Clin Infect Dis200337341542512884167
   PubMed Web of Science ®Google Scholar
• WingardJRWhiteMHAnaissieERaffalliJGoodmanJArrietaAA randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study GroupClin Infect Dis20003151155116311073745
   PubMed Web of Science ®Google Scholar
• SafdarAMaJSalibaFDrug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysisMedicine (Baltimore)201089423624420616663
   PubMed Web of Science ®Google Scholar
• WalshTJFinbergRWArndtCLiposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study GroupN Engl J Med19993401076477110072411
   PubMed Web of Science ®Google Scholar
• WalshTJTepplerHDonowitzGRCaspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropeniaN Engl J Med20043511401391140215459300
   PubMed Web of Science ®Google Scholar
• MaertensJAMaderoLReillyAFA randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropeniaPediatr Infect Dis J201029541542020431381
   PubMed Web of Science ®Google Scholar
• EllisMFramptonCJosephJAn open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancyJ Med Microbiol200655Pt 101357136517005784
   PubMed Web of Science ®Google Scholar
• WalshTJPappasPWinstonDJVoriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent feverN Engl J Med2002346422523411807146
   PubMed Web of Science ®Google Scholar
• USA FDA Regulations http://www.fda.gov/drugs/default.htm
   Google Scholar
• ChenSCSlavinMASorrellTCEchinocandin antifungal drugs in fungal infections: a comparisonDrugs2011711114121175238
   PubMed Web of Science ®Google Scholar
• KubiakDWBryarJMMcDonnellAMEvaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysisClin Ther201032463764820435233
   PubMed Web of Science ®Google Scholar
• WaknineYFDA approvalsAvelox, Avandaryl, Trileptal Available at: http://www.medscape.com/viewarticle/518278?rssAccessed February 11, 2006 [cited 2011 Oct 24]
   Google Scholar